MSCI Schedules Investor Conference Call to Review Second Quarter 2019 Results
MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today it will release its results for second quarter 2019 on Thursday, August 1, 2019.
MSCI's senior management will review the second quarter 2019 results on Thursday, August 1, 2019 at 11:00 AM Eastern Time. To listen to the live event, visit the events and presentations section of MSCI's Investor Relations homepage, http://ir.msci.com/events.cfm, or dial 1-877-376-9931 conference ID: 7743929 within the United States. International callers dial 1-720-405-2251 conference ID: 7743929. The earnings release and related investor presentation used during the conference call will be made available on MSCI's Investor Relations homepage.
An audio recording of the conference call will be available on our Investor Relations website, http://ir.msci.com/events.cfm, beginning approximately two hours after the conclusion of the live event. Through August 4, 2019, the recording will also be available by dialing 1-855-859-2056 conference ID: 7743929 within the United States or 1-404-537-3406 conference ID: 7743929 for international callers. A replay of the conference call will be archived in the events and presentations section of MSCI's Investor Relations website for 12 months after the call.
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 45 years of expertise in research, data and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading, research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process.
To learn more, please visit www.msci.com. MSCI#IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190716005696/en/
Contact information
MSCI Inc.
Investors Inquiries
Linda Huber, CFO investor.relations@msci.com +1 646 465 7043
Media Inquiries
PR@msci.com
Sam Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura Hudson +44 20 7336 9653
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 15:31:00 EET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 15:00:00 EET | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). Anterior uveitis is an inflammation of the inner eye including the iris and ciliary body, that typically causes a red, painful, light‑sensitive eye and can lead to vision loss if not treated promptly. NIAU represents 67-90% of uveitis cases in the developed world.1 To treat uveitis a drug must reach the uveal tract inside the eye. Current treatment choices are limited to corticosteroid eye drops and, if insuffic
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 15:00:00 EET | Press release
Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise environments that demand both performance and trust. “Lucend’s Transparent AI platform analyzes billions of data points daily and provides prescriptive recommendations that
IQM Quantum Computers Appoints Jan Goetz as Sole CEO to Lead Next Phase of Global Growth26.1.2026 11:15:00 EET | Press release
IQM Quantum Computers, a global leader in full-stack superconducting quantum computers, today announced a transition from its Co-CEO structure to a single Chief Executive Officer model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126737805/en/ From left to right: Jan Goetz (Co-founder & CEO) and Søren Hein (Chief Operating Officer and Deputy CEO) Co-founder and current Co-CEO Dr Jan Goetz becomes sole CEO effective since January 1st, following a resolution passed by the IQM board. In addition, Dr Søren Hein has been appointed Chief Operating Officer and Deputy CEO. As part of the transition, Mikko Välimäki steps down from his commercial role following a successful tenure as Co-CEO. He will continue to support the company as an advisor until 31 March 2026 to ensure continuity and a smooth transition. “Our dual CEO approach has served IQM well over the past two years, and I want to thank Mikko Välimäki for his significan
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 10:00:00 EET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom